UCB SA Valuation
| UCBJY Stock | USD 101.30 0.39 0.39% |
At this time, the entity appears to be undervalued. UCB SA ADR owns a latest Real Value of $114.0 per share. The recent price of the entity is $101.3. Our model measures the value of UCB SA ADR from evaluating the entity fundamentals such as Price To Earning of 17.55 X, profit margin of 0.15 %, and Return On Asset of 0.0468 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that UCB SA's price fluctuation is very steady at this time. Calculation of the real value of UCB SA ADR is based on 3 months time horizon. Increasing UCB SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since UCB SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of UCB Pink Sheet. However, UCB SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 101.3 | Real 114.0 | Hype 101.33 | Naive 102.57 |
The intrinsic value of UCB SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence UCB SA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of UCB SA ADR helps investors to forecast how UCB pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of UCB SA more accurately as focusing exclusively on UCB SA's fundamentals will not take into account other important factors: UCB SA Total Value Analysis
UCB SA ADR is at this time forecasted to have takeover price of 16.62 B with market capitalization of 15.86 B, debt of 1.97 B, and cash on hands of 515 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the UCB SA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.62 B | 15.86 B | 1.97 B | 515 M |
UCB SA Investor Information
The company has Price to Book (P/B) ratio of 1.55. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. UCB SA ADR last dividend was issued on the 29th of April 2022. Based on the key measurements obtained from UCB SA's financial statements, UCB SA ADR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.UCB SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. UCB SA has an asset utilization ratio of 40.65 percent. This suggests that the Company is making $0.41 for each dollar of assets. An increasing asset utilization means that UCB SA ADR is more efficient with each dollar of assets it utilizes for everyday operations.UCB SA Profitability Analysis
The company reported the revenue of 5.78 B. Net Income was 1.06 B with profit before overhead, payroll, taxes, and interest of 4.34 B.About UCB SA Valuation
Our relative valuation model uses a comparative analysis of UCB SA. We calculate exposure to UCB SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of UCB SA's related companies.UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people.
8 Steps to conduct UCB SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates UCB SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct UCB SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain UCB SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine UCB SA's revenue streams: Identify UCB SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research UCB SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish UCB SA's growth potential: Evaluate UCB SA's management, business model, and growth potential.
- Determine UCB SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate UCB SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
UCB SA Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 194.2 M | |
| Quarterly Earnings Growth Y O Y | -0.303 | |
| Forward Price Earnings | 17.5439 | |
| Retained Earnings | 6.3 B |
Additional Tools for UCB Pink Sheet Analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.